InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
Puromycin | A parasite DNA binding protein with potential to influence disease susceptibi... | 2023 | PLoS One | Durrani Z. et al. | DOI: 10.1371/journal.pone.0286526 |
G418 (Geneticin) | A parasite DNA binding protein with potential to influence disease susceptibi... | 2023 | PLoS One | Durrani Z. et al. | DOI: 10.1371/journal.pone.0286526 |
Human TLR4 Reporter HEK293 Cells (NF-κB) | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
HEK-Blue™ Detection | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
Pam3CSK4 | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
Human TLR2 Reporter HEK293 Cells (NF-κB) | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
HEK-Blue™ Selection | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
OxPAPC | Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. | 2023 | mSphere | Mursalin M.H. et al. | DOI: 10.1128/msphere.00044-23 |
Normocin® - Antimicrobial Reagent | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
Zeocin® | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
Blasticidin | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
Human TLR9 Reporter HEK293 Cells (NF-κB) | Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signali... | 2023 | Clin Exp Immunol. | Hashimoto T. et al. | DOI: 10.1093/cei/uxad064 |
Plasmocin® - Mycoplasma Elimination Reagent | Soluble monomeric human programmed cell death-ligand 1 inhibits the functions... | 2023 | Front Immunol. | Liang Z. et al. | DOI: 10.3389/fimmu.2023.1133883 |
Puromycin | Kremen2 drives the progression of non-small cell lung cancer by preventing SO... | 2023 | J Exp Clin Cancer Res. | Sun Y. et al. | DOI: 10.1186/s13046-023-02692-3 |
STING inhibitor | Role of the cGAS/STING pathway in the control of Brucella abortus infection a... | 2023 | Front Immunol. | Alonso Paiva I.M. et al. | DOI: 10.3389/fimmu.2023.1116811 |
Imiquimod (R837) | Activation of TLR7-mediated autophagy increases epileptic susceptibility via ... | 2023 | Exp Mol Med. | Liu J. et al. | DOI: 10.1038/s12276-023-01000-5 |
293XL/TLR7 | Engineered tRNAs suppress nonsense mutations in cells and in vivo. | 2023 | Nature | Albers S. et al. | DOI: 10.1038/s41586-023-06133-1 |
293XL/TLR8 | Engineered tRNAs suppress nonsense mutations in cells and in vivo. | 2023 | Nature | Albers S. et al. | DOI: 10.1038/s41586-023-06133-1 |
Imiquimod (R837) | Prolonged inflammatory resolution in allergic asthma relates to dysfunctional... | 2023 | Ann Allergy Asthma Immunol. | Ekstedt S. et al. | DOI: 10.1016/j.anai.2023.05.030 |
QUANTI-Blue™ | Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients wit... | 2023 | J Interferon Cytokine Res. | Vanker M. et al. | DOI: 10.1089/jir.2023.0003 |